|
**Overview**: Fragile X FMR1 Mutation Panel**Introduction**: The Fragile X FMR1 Mutation Panel is a diagnostic tool designed to screen for Fragile X syndrome using whole blood samples. In India, Fragile X syndrome (CGG repeat expansion in FMR1) is the most common inherited cause of intellectual disability (~1 in 4,000â€"7,000 males), with full mutation (>200 repeats) causing moderate-severe ID, autism features, and macroorchidism. High morbidity from underdiagnosis in rural/low-SES children with developmental delay, limited genetic labs, delayed behavioral/educational intervention leading to lifelong disability. Per molecular pathology practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for FMR1 CGG repeats and methylation status over 1-2 days with high accuracy, valuable for confirming diagnosis in suspected cases. This diagnostic falls under genetic disorder screening and targets children with ID, autism, or family history, addressing accurate detection to guide therapy and family counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing intellectual disability burden. Its whole blood-based approach ensures reliable repeat expansion analysis.**Other Names**: Fragile X Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: FMR1 PCR standard; in India, used in developmental clinics.**Purpose**: The test assesses 2 parameters including FMR1 CGG repeats to guide Fragile X screening, detect expansion/methylation, inform management.**Test Parameters**: 1. FMR1 CGG Repeats, 2. Methylation Status.**Pretest Condition**: No fasting required; patients should have suspected Fragile X features.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on developmental delay, autism features, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed Fragile X including disability, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Full mutation (>200 repeats) confirms Fragile X, necessitating specialist input. Premutation may require follow-up.**Specialist Consultation**: Pediatric geneticists should be consulted for management.**Additional Supporting Tests**: Methylation PCR, Southern blot for confirmation.**Test Limitations**: Detects CGG expansion only; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Genetic Studies India 2023. |
